Ultragenyx’s Genglycos approval opens a new rare-disease market

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has won US regulatory approval for Genglycos, its first gene therapy and fifth U.S. Food and Drug Administration-approved product, opening a new commercial opportunity in glycogen storage disease type Ia (GSDIa), a rare metabolic disorder. The FDA’s accelerated approval makes Genglycos the first treatment for GSDIa designed to address the disease’s underlying genetic cause, rather than relying solely on dietary management.

The opportunity is sizeable relative to the small patient population. Visible Alpha consensus shows Genglycos revenue of $9 million in 2026, rising to $53 million in 2027, its first full year on the market, and reaching a peak global sales of $294 million in 2033 before declining as patent protection expires and generic competition emerges.

The approval puts Ultragenyx at the forefront of a nascent GSDIa treatment market. Moderna’s (NASDAQ: MRNA) mRNA-3745 is being tested in an early-stage study, while Beam Therapeutics’ (NASDAQ: BEAM) BEAM-301 is in a Phase 1/2 trial. Both aim to address the underlying genetic defect, potentially creating competition for Genglycos if they progress successfully.

This article was published by Visible Alpha, part of S&P Global Market Intelligence and not by S&P Global Ratings, which is a separately managed division of S&P Global.